RHĂ–N-KLINIKUM AG / Key word(s): Mergers & Acquisitions/Forecast

09.02.2012 20:25

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - adhoc company of EquityStory AG. The issuer is solely responsible for the content of this announcement.

Ad hoc notice according to section 15 German Securities Trading Act (WpHG)

RHĂ–N-KLINIKUM AG

- City of Wiesbaden in favour of RHĂ–N-KLINIKUM AG acquiring equity interest in Dr.-Horst-Schmidt-Kliniken.

- Outlook for 2012 is refined

Bad Neustadt a.d. Saale, 9 February 2012

By a large majority, Wiesbaden City Council today gave its approval for the sale of a 49 per cent equity interest in Dr.-Horst-Schmidt-Kliniken (HSK) to RHĂ–N-KLINIKUM AG. As part of this interest, the private hospital operator is to assume entrepreneurial management of the biggest hospital in Wiesbaden, Federal State Capital of Hesse, and to also initiate the refurbishment and modernisation of its building infrastructure.

'We are pleased with the tremendous trust the city councillors and Wiesbaden City Council have placed in us. With our restructuring expertise, we will return HSK to profit and make it a viable facility', said Wolfgang Pföhler, chairman of the Board of Management of RHÖN-KLINIKUM AG.

Each year, Dr.-Horst-Schmidt-Kliniken treats a total of roughly 43 thousand patients in 1,027 beds and generates revenues of over EUR 200 million. As a maximum-care hospital, HSK employs roughly 3,100 employees at three sites.

Execution of the transaction requires formal approval by the social, municipal supervisory and cartel authorities, and is moreover subject to the reservation of a possible referendum opposing the share's sale. The two parties agreed to maintain secrecy regarding the purchase price.

As part of this recent participating interest, the Group refines its forecast for the current financial year to also include a first-time consolidation of HSK slated for the second quarter of 2012. For 2012 including HSK, RHĂ–N-KLINIKUM AG expects revenues of EUR 2.85 billion which may fluctuate within a range of plus or minus 2.5 per cent. This revenue target is accompanied by a forecast for EBITDA of EUR 350 million and for net consolidated profit of EUR 145 million - in each case influenced by a negative earnings contribution from the HSK consolidation and subject to a fluctuation range of plus or minus five per cent. In the event of the first-time consolidation of HSK being delayed, adjustments to individual revenue and earnings figures may become necessary during the year.

The Board of Management

Contact:

Dr. Kai G. Klinger Head of Investor Relations

RHĂ–N-KLINIKUM AG Corporate Division of Finance, Investor Relations, Controlling Schlossplatz 1 D-97616 Bad Neustadt a. d. Saale

Tel.: +49 (0)9771-65.13 18 Fax: +49 (0)9771-99.17 36 Mobile: +49 (0)151-12 58 27 07 E-mail: kai.klinger@rhoen-klinikum-ag.com web: http://www.rhoen-klinikum-ag.com

Chairman of the Supervisory Board: Eugen Münch Board of Management: Wolfgang Pföhler (chairman), Volker Feldkamp, Dr. Erik Hamann, Martin Menger, Dr. Irmgard Stippler Registered office of Company: Bad Neustadt a. d. Saale Register Court of Schweinfurt HRB 1670

09.02.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de



Language: English
Company: RHĂ–N-KLINIKUM AG
Schlossplatz 1
97616 Bad Neustadt a.d.Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Indices: MDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard), MĂĽnchen;
Freiverkehr in Berlin, DĂĽsseldorf, Hamburg, Stuttgart

End of Announcement DGAP News-Service